MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting
Clinical Trials
Related News

Protagenic and Phytanix Merge to Form Neuroactive Biopharmaceutical Company with Obesity Drug in Development

• Protagenic Therapeutics and Phytanix Bio have completed an all-stock business combination to form Phytanix, Inc., creating a pipeline of six drug candidates focused on stress-related and CNS disorders. • The merged company's portfolio includes a proprietary cannabinoid-based molecule targeting obesity and metabolic disorders, potentially competing in the lucrative GLP-1 agonist market. • The combined entity brings together clinical and preclinical assets with significant milestones expected in the next 18 months, leveraging expertise from team members who previously worked on approved cannabinoid medications.

Jazz Pharmaceuticals Reports Strong Q1 2025 Performance with $898 Million in Revenue, Advances Pipeline with Zepzelca sNDA Submission

• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively. • The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results. • Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.

New Phospholipid Complex Boosts CBD Bioavailability for Epilepsy and MS Treatment

• University of South Australia researchers have developed a phospholipid complex that increases cannabidiol solubility by up to six times, significantly enhancing its absorption in the gastrointestinal tract. • The breakthrough formulation showed 67.1% dissolution in water within three hours and 32.7% higher permeability through intestinal walls compared to unmodified CBD, potentially reducing required dosages and side effects. • Unlike traditional CBD formulations that degrade when exposed to heat, light, or oxygen, the new CBD-PLC maintained stability over 12 months of testing under varied storage conditions, making it more reliable for pharmaceutical applications.

DeFloria's AJA001: A Novel Botanical Drug for Autism Spectrum Disorder Advances to Phase 2 Trials

• DeFloria, a joint venture involving Charlotte's Web, is developing AJA001, a multi-cannabinoid botanical drug, for treating Autism Spectrum Disorder (ASD). • AJA001 has completed Phase 1 trials, demonstrating safety and a favorable pharmacokinetic profile, paving the way for Phase 2 studies. • The Phase 2 trials, planned for the second quarter of 2025, will evaluate AJA001's efficacy in children, adolescents, and adults with ASD. • AJA001 represents a unique approach as the first oral systemic full-spectrum botanical drug to navigate the FDA approval process.

IGC Pharma's CALMA Trial for Alzheimer's Agitation Boosts Enrollment with Innovative AI Strategy

• IGC Pharma's Phase 2 clinical trial for Alzheimer's agitation is now officially named CALMA (Calming Agitation in Alzheimer's). • The CALMA trial addresses agitation, a syndrome affecting up to 76% of Alzheimer's patients, impacting their quality of life. • IGC Pharma leverages geofencing and social media to increase enrollment, achieving a 200-300% rise at select sites. • The company aims to complete the CALMA trial in the second half of 2025, advancing IGC-AD1 as a potential treatment.

Cannabinoids Show Promise in Managing Peripheral Neuropathy Symptoms

• A systematic review of 14 clinical trials indicates that cannabis-based medicines may effectively treat peripheral neuropathy by reducing neuropathic pain. • The review, published in _The Journal of Hand Surgery_, found that 79% of studies reported improvements in neuropathic pain with cannabinoid treatments. • Secondary benefits, including enhanced sleep quality, reduced anxiety, and improved quality of life, were also observed in several studies with mild side effects. • Data suggests cannabis is used by chronic pain patients as an analgesic, often substituting opioids, highlighting its potential role in pain management.

FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management

• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids. • Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids. • Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations. • Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.

CBD Shows Potential for Reducing Anxiety in Women with Advanced Breast Cancer

• A phase II trial explored CBD's effect on anxiety in women with advanced breast cancer before scans, a common trigger for anxiety. • While the primary endpoint of significant anxiety reduction wasn't met, patients reported lower anxiety levels 2-4 hours after CBD ingestion. • The study suggests CBD is safe for anxiety management in this population, warranting further investigation into its anxiolytic properties. • Researchers emphasize the need for larger trials to validate CBD's efficacy and explore its role in cancer-related anxiety treatment.

DeFloria's AJA001 Shows Promise in Phase 1 Trial for Autism Spectrum Disorder

• DeFloria's AJA001, a multi-cannabinoid botanical drug, demonstrated safety and tolerability in a Phase 1 trial involving 70 healthy volunteers. • The trial showed dose-proportional pharmacokinetics for CBD and THC, with plasma concentrations comparable to existing cannabinoid therapeutics. • AJA001's pharmacodynamic effects correlated with THC levels, supporting doses up to 660 mg/day for Phase 2 trials in ASD patients. • The company plans to submit Phase 1 data to the FDA and initiate Phase 2 trials in Q2 2025 to assess AJA001's impact on ASD symptoms.

FDA Approves Clinical Trial of Smoked Cannabis for PTSD Treatment in Veterans

• The FDA has approved a Phase 2 clinical trial to study the safety and efficacy of smoked cannabis for treating PTSD symptoms in veterans. • The trial, funded by the Michigan Veteran Marijuana Research Grant Program, will involve 320 veterans with moderate to severe PTSD. • Researchers will investigate the effects of self-titrated doses of high-THC cannabis flower compared to a placebo, mirroring real-world consumption. • The FDA's decision marks a shift towards recognizing the potential value of cannabis research and its impact on informing medical use.

Study Shows Reducing Cannabis Use Significantly Improves Outcomes for Patients

• A new study demonstrates that reducing cannabis use, even without complete abstinence, leads to clinically meaningful improvements in patients with cannabis use disorder. • The research indicates that a 50% reduction in days of use and a 75% reduction in use amounts are associated with maximum improvements in clinical global impressions. • These findings support the development of new treatments for cannabis use disorder, potentially broadening FDA approval criteria beyond total abstinence. • The study highlights the importance of focusing on harm reduction strategies and setting achievable therapeutic goals for individuals with substance use disorders.

Ananda Developments Advances Cannabinoid Medicines in Phase III Epilepsy Trials

• Ananda Developments' MRX2 and MRX2T formulations selected for two Phase III trials targeting drug-resistant epilepsies, funded by NIHR and NHS England. • The trials will assess the safety and efficacy of CBD and CBD+THC in reducing seizure frequency and improving quality of life in 500 patients. • Ananda's MRX1 formulation demonstrates cardioprotective effects in preclinical studies for Heart Fibrosis with Preserved Ejection Fraction (HFpEF). • A Phase 1 pharmacokinetic study of MRX1 is underway in Australia, leveraging R&D tax incentives to support regulatory applications.

NHS to Launch Clinical Trials of Cannabis-Based Medicines for Refractory Epilepsy in 2025

• Two NHS clinical trials are set to begin in 2025 to evaluate the safety and efficacy of cannabidiol (CBD) and tetrahydrocannabinol (THC) for treatment-resistant epilepsy. • The trials, led by UCL and Great Ormond Street Hospitals, will involve 500 adults and children with early-onset and genetic generalized epilepsies. • Researchers aim to determine if CBD and THC reduce seizure frequency and severity, while also assessing impacts on learning, sleep, behavior, and overall quality of life. • The trials will use formulations by Ananda Developments and could support regulatory approval for cannabis-based medicines in refractory epilepsy if successful.

Olanzapine and Cannabis Extracts Show Promise in Managing Chemotherapy-Induced Nausea

• A study at ASCO found olanzapine significantly reduces severe nausea in breast cancer patients undergoing chemotherapy, especially when standard antiemetics are insufficient. • Research published in the Journal of Clinical Oncology indicates that a cannabis extract with THC/CBD effectively reduces nausea and vomiting during chemotherapy. • Olanzapine proves more effective than prochlorperazine for severe nausea, improving patients' quality of life during chemotherapy cycles. • A THC/CBD cannabis extract demonstrated a higher complete response rate compared to placebo, though with increased side effects like sedation and dizziness.

Ananda Developments' Cannabinoid Medicines to be Used in NHS Epilepsy Trials

• Ananda Developments' MRX2 and MRX2T will be used in two Phase IIIa epilepsy clinical trials funded by NIHR and NHS, involving up to 500 patients. • The trials will investigate MRX2 (CBD) and MRX2T (CBD + THC) versus placebo for refractory early-onset and genetic generalized epilepsies. • These trials are designed to support marketing authorization applications for MRX2 & MRX2T, potentially leading to further regulatory and commercial development. • The studies represent the largest investigational trials to date for cannabinoids as a treatment for refractory epilepsy, addressing a significant unmet need.

CBG Shows Promise in Reducing Anxiety and Enhancing Verbal Memory

• A double-blind, placebo-controlled study found that cannabigerol (CBG) significantly reduced overall feelings of anxiety in cannabis users. • Participants reported no intoxication or significant side effects, and CBG did not impair cognitive or motor functions. • Surprisingly, CBG enhanced verbal memory at 45- and 60-minute check-ins, a finding that warrants further investigation. • The study provides initial scientific evidence supporting the anecdotal use of CBG for anxiety relief, distinguishing it from THC's effects.

Jazz Pharmaceuticals Acquires GW Pharma in $7.2B Cannabis Medicine Deal

• Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals for $7.2 billion, marking a significant expansion into cannabis-derived medicines and creating a leader in neuroscience therapeutics. • GW's flagship product Epidiolex, the first FDA-approved cannabis-based medicine, achieved $510 million in sales in 2020 and holds patent protection until at least 2035. • The acquisition diversifies Jazz's portfolio beyond its narcolepsy drug Xyrem and includes GW's late-stage pipeline candidate nabiximols, currently in Phase 3 trials for MS spasticity.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy